Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Silke R. Brix, MD, MRCP, SCPR
NIHR Senior Clinician Practitioner Researcher
Consultant in Nephrology and Vasculitis, Manchester Royal Infirmary
Honorary Senior Lecturer, Manchester University
Manchester, United Kingdom
Dr. Brix has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, Roche
Bernhard Hellmich, MD
Chair, Department of Medicine
Medius Kliniken, University of Tübingen
Baden-Württemberg, Germany
Dr. Hellmich has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Astra Zeneca, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, Novartis
Royalties: AbbVie, Amgen, BMS, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, MSD, Novartis, Pfizer, Phadia, Roche
Andreas Kronbichler, MD
Assistant Professor of Medicine
Medical University of Innsbruck
Innsbruck, Austria
Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
Contracted Research: CSL Vifor
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity has been designed to meet the educational needs of nephrologists, nephrology nurses, rheumatologists, and renal pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with AAV.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 contact hour(s)/0.05 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-013-H01-P. This learning activity is knowldge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until February 14, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 45 minutes of effective education time.
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from CSL Vifor.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Release Date:
Expiration Date:
